Clark D A, Dessypris E N, Krantz S B
Blood. 1984 Feb;63(2):277-86.
Thirty-seven patients with pure red cell aplasia (PRCA) were seen between 1966 and 1982. Ten patients had accompanying diseases described in association with PRCA, while the remainder had primary PRCA. All but two patients were treated with some form of immune manipulation, including corticosteroids, cytotoxic drugs, antithymocyte globulin, splenectomy, thymectomy, and plasmapheresis. Twenty-three patients (66%) had a remission induced by immunosuppression. In addition, there were 5 spontaneous remissions (14%). Cytotoxic drugs administered in combination with corticosteroids were the most effective form of treatment, producing 18/32 remissions (56%). Twelve of these remissions were in patients resistant to corticosteroids or in patients who had relapsed while taking them. Thirteen of the 23 patients in whom remissions were induced and one-fifth of the patients with spontaneous remissions have relapsed to date. However, with additional treatment, a second remission was induced in 10/13. Fifty-four percent of the patients with induced remissions remained transfusion-free during most of the follow-up period. Median survival in patients with primary PRCA was greater than 10 yr, whereas in patients with secondary PRCA, it was 4 yr. Infection was a major cause of morbidity and mortality. This study demonstrates the value of a variety of immunosuppressive treatments of patients with PRCA.
1966年至1982年间共诊治了37例纯红细胞再生障碍性贫血(PRCA)患者。10例患者伴有与PRCA相关的疾病,其余患者为原发性PRCA。除2例患者外,所有患者均接受了某种形式的免疫干预治疗,包括使用皮质类固醇、细胞毒性药物、抗胸腺细胞球蛋白、脾切除术、胸腺切除术和血浆置换术。23例患者(66%)通过免疫抑制诱导缓解。此外,有5例自发缓解(14%)。联合使用皮质类固醇的细胞毒性药物是最有效的治疗方式,产生了18/32例缓解(56%)。其中12例缓解发生在对皮质类固醇耐药的患者或服用皮质类固醇期间复发的患者中。在诱导缓解的23例患者中,有13例复发,自发缓解的患者中有五分之一至今复发。然而,经过额外治疗,10/13例患者再次诱导缓解。诱导缓解的患者中有54%在大部分随访期间无需输血。原发性PRCA患者的中位生存期超过10年,而继发性PRCA患者的中位生存期为4年。感染是发病和死亡的主要原因。本研究证明了对PRCA患者进行多种免疫抑制治疗的价值。